Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 12230-12232 [2017-03948]
Download as PDF
<![CDATA[
12230
Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 21, 2017.
Closed Committee Deliberations: On
April 5, 2017, from 11:15 a.m. to 12:00
p.m., the meeting will be closed to
permit discussion where disclosure
would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The Committee will discuss
the report of the intramural research
program and make recommendations
regarding personnel staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Bryan Emery
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 24, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2017–03944 Filed 2–28–17; 8:45 am]
BILLING CODE 4164–01–P
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Biomedical
Engineering.
Date: March 2–3, 2017.
Time: 8:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Joseph D Mosca, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158,
MSC 7808, Bethesda, MD 20892, (301) 435–
2344, moscajos@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Health Services Organization and
Delivery.
Date: March 6, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Gabriel B Fosu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
MSC 7808, Bethesda, MD 20892, (301) 435–
3562, fosug@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 23, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2017–03903 Filed 2–28–17; 8:45 am]
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
18:09 Feb 28, 2017
Jkt 241001
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
E:\FR\FM\01MRN1.SGM
01MRN1
Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW.,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
844–486–9226.
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories).
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center—Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
Dynacare,* 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories).
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Fortes Laboratories, Inc., 25749 SW
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–
1023.
VerDate Sep<11>2014
18:09 Feb 28, 2017
Jkt 241001
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088, Testing for Veterans Affairs
(VA) Employees Only.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, In,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840.
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
12231
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories).
Redwood Toxicology Laboratory, 3700
Westwind Blvd., Santa Rosa, CA
95403, 800–255–2159.
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438.
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only.
The following laboratory has
voluntarily withdrawn from the
National Laboratory Certification
Program, as of January 6, 2017:
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027.
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on November 25, 2008 (73 FR
71858). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
E:\FR\FM\01MRN1.SGM
01MRN1
12232
Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices
the NLCP certification maintenance
program.
Brian Makela,
Chemist.
[FR Doc. 2017–03948 Filed 2–28–17; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of
Inspectorate America Corporation, as a
Commercial Gauger and Laboratory
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Inspectorate America
Corporation as a commercial gauger and
laboratory.
AGENCY:
Notice is hereby given,
pursuant to CBP regulations, that
Inspectorate America Corporation has
SUMMARY:
been approved to gauge petroleum and
certain petroleum products and
accredited to test petroleum and certain
petroleum products for customs
purposes for the next three years as of
June 16, 2016.
DATES: The accreditation and approval
of Inspectorate America Corporation as
commercial gauger and laboratory
became effective on June 16, 2016. The
next triennial inspection date will be
scheduled for June 2019.
FOR FURTHER INFORMATION CONTACT:
Approved Gauger and Accredited
Laboratories Manager, Laboratories and
Scientific Services Directorate, U.S.
Customs and Border Protection, 1300
Pennsylvania Avenue NW., Suite
1500N, Washington, DC 20229, tel. 202–
344–1060.
SUPPLEMENTARY INFORMATION: Notice is
hereby given pursuant to 19 CFR 151.12
and 19 CFR 151.13, that Inspectorate
America Corporation, 33 Rigby Road,
South Portland, ME 04106 has been
approved to gauge petroleum and
certain petroleum products and
accredited to test petroleum and certain
petroleum products for customs
purposes, in accordance with the
provisions of 19 CFR 151.12 and 19 CFR
151.13. Inspectorate America
Corporation is approved for the
following gauging procedures for
petroleum and certain petroleum
products from the American Petroleum
Institute (API):
API Chapters
3 .....................
7 .....................
8 .....................
9 .....................
12 ...................
17 ...................
Title
Tank Gauging
Temperature Determination
Sampling
Density Determination
Calculations
Marine Measurement
Inspectorate America Corporation is
accredited for the following laboratory
analysis procedures and methods for
petroleum and certain petroleum
products set forth by the U.S. Customs
and Border Protection Laboratory
Methods (CBPL) and American Society
for Testing and Materials (ASTM):
ASTM
Title
27–04 ..............
27–06 ..............
27–11 ..............
D 95 ...............
D 473 .............
D 445 .............
27–13 ..............
D 4294 ...........
27–46 ..............
asabaliauskas on DSK3SPTVN1PROD with NOTICES
CBPL No.
D 5002 ...........
Standard Test Method for Water in Petroleum Products and Bituminous Materials by Distillation.
Standard Test Method for Sediment in Crude Oils and Fuel Oils by the Extraction Method.
Standard Test Method for Kinematic Viscosity of Transparent and Opaque Liquids (and Calculation of Dynamic Viscosity).
Standard Test Method for Sulfur in Petroleum and Petroleum Products by Energy Dispersive X-ray Fluorescence Spectrometry.
Standard Test Method for Density and Relative Density of Crude Oils by Digital Density Analyzer.
Anyone wishing to employ this entity
to conduct laboratory analyses and
gauger services should request and
receive written assurances from the
entity that it is accredited or approved
by the U.S. Customs and Border
Protection to conduct the specific test or
gauger service requested. Alternatively,
inquiries regarding the specific test or
gauger service this entity is accredited
or approved to perform may be directed
to the U.S. Customs and Border
Protection by calling (202) 344–1060.
The inquiry may also be sent to
CBPGaugersLabs@cbp.dhs.gov. Please
reference the Web site listed below for
a complete listing of CBP approved
gaugers and accredited laboratories.
https://www.cbp.gov/about/labsscientific/commercial-gaugers-andlaboratories.
Dated: February 23, 2017.
Ira S. Reese,
Executive Director, Laboratories and
Scientific Services Directorate.
[FR Doc. 2017–03992 Filed 2–28–17; 8:45 am]
BILLING CODE 9111–14–P
VerDate Sep<11>2014
18:09 Feb 28, 2017
Jkt 241001
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Approval of Inspectorate America
Corporation, as a Commercial Gauger
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of approval of
Inspectorate America Corporation as a
commercial gauger.
AGENCY:
Notice is hereby given,
pursuant to CBP regulations, that
Inspectorate America Corporation has
been approved to gauge petroleum and
certain petroleum products for customs
purposes for the next three years as of
June 21, 2016.
DATES: The approval of Inspectorate
America Corporation as commercial
gauger became effective on June 21,
2016. The next triennial inspection date
will be scheduled for June 2019.
FOR FURTHER INFORMATION CONTACT:
Approved Gauger and Accredited
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Laboratories Manager, Laboratories and
Scientific Services Directorate, U.S.
Customs and Border Protection, 1300
Pennsylvania Avenue NW., Suite
1500N, Washington, DC 20229, tel. 202–
344–1060.
Notice is
hereby given pursuant to 19 CFR 151.13,
that Inspectorate America Corporation,
3000 N. Main Street, Suite 1B, Baytown,
TX 77251, has been approved to gauge
petroleum and certain petroleum
products for customs purposes, in
accordance with the provisions of 19
CFR 151.13. Inspectorate America
Corporation is approved for the
following gauging procedures for
petroleum and certain petroleum
products from the American Petroleum
Institute (API):
SUPPLEMENTARY INFORMATION:
API chapters
Title
3 .....................
5 .....................
7 .....................
8 .....................
12 ...................
Tank Gauging.
Metering.
Temperature Determination.
Sampling.
Calculations.
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Pages 12230-12232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03948]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines).
A notice listing all currently HHS-certified laboratories and IITFs
is published in the Federal Register during the first week of each
month. If any laboratory or IITF certification is suspended or revoked,
the laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.samhsa.gov/workplace.
FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240-276-2600 (voice).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) notifies federal agencies of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently certified to meet the
standards of the Mandatory Guidelines for Federal Workplace Drug
Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were
first published in the Federal Register on April 11, 1988 (53 FR
11970), and subsequently revised in the Federal Register on June 9,
1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004
(69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73
FR 75122); and on April 30, 2010 (75 FR 22809).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71. The
``Mandatory Guidelines for Federal Workplace Drug Testing Programs,''
as amended in the revisions listed above, requires strict standards
that laboratories and IITFs must meet in order to conduct drug and
specimen validity tests on urine specimens for federal agencies.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance
[[Page 12231]]
testing program plus undergo periodic, on-site inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA),
which attests that it has met minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following HHS-certified laboratories and IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
HHS-Certified Instrumented Initial Testing Facilities
Dynacare, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780-784-
1190, (Formerly: Gamma-Dynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
844-486-9226.
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN
37210, 615-255-2400, (Formerly: Aegis Sciences Corporation, Aegis
Analytical Laboratories, Inc., Aegis Analytical Laboratories).
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center--Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center).
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917.
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890.
Dynacare,* 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630, (Formerly: Gamma-Dynacare Medical Laboratories).
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609.
Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503-486-1023.
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group).
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088,
Testing for Veterans Affairs (VA) Employees Only.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, In, 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204, 509-755-8991/800-541-7891x7.
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084,
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical
Laboratories).
Redwood Toxicology Laboratory, 3700 Westwind Blvd., Santa Rosa, CA
95403, 800-255-2159.
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for
Department of Defense (DoD) Employees Only.
The following laboratory has voluntarily withdrawn from the
National Laboratory Certification Program, as of January 6, 2017:
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on November 25, 2008 (73 FR 71858).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in
[[Page 12232]]
the NLCP certification maintenance program.
Brian Makela,
Chemist.
[FR Doc. 2017-03948 Filed 2-28-17; 8:45 am]
BILLING CODE 4162-20-P
